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Abstract
Endogenous and synthetic glucocorticoids (GCs) regulate epidermal development and combat skin inﬂammatory
diseases. GC actions can be mediated through the GC receptor (GR) and/or the mineralocorticoid receptor (MR), highly
homologous ligand-activated transcription factors. While the role of GR as a potent anti-inﬂammatory mediator is well
known, that of MR is not as clear, nor is whether these receptors cooperate or antagonize each other in the epidermis. To
address this, we generated mice with epidermal-speciﬁc loss of both receptors (double knockout, DKO), and analyzed the
phenotypical and functional consequences relative to single KOs or controls (CO). At birth, DKO epidermis displayed a
phenotype of defective differentiation and inﬂammation, which was more severe than in either single KO, featuring
neutrophil-containing inﬁltrates, and gene dysregulation characteristic of human psoriatic lesions. This phenotype resolved
spontaneously. However, in adulthood, single or combined loss of GC receptors increased susceptibility to inﬂammation
and hyperproliferation triggered by phorbol ester which, different to CO, was not effectively counteracted by GC
treatment. Also, DKOs were more susceptible to imiquimod-induced psoriasis than CO showing severe defective
epidermal differentiation and microabcesses while single KOs showed an intermediate response. Immortalized DKO
keratinocytes featured increased proliferation kinetics and reduced cell size, a unique phenotype relative to single KO cells.
The lack of GR and MR in keratinocytes, individual or combined, caused constitutive increases in p38 and ERK activities,
which were partially reversed upon reinsertion of receptors into DKO cells. DKO keratinocytes also displayed signiﬁcant
increases in AP-1 and NF-κB transcriptional activities, which were partially rescued by ERK and p38 inhibition, respectively.
Reinsertion of GR and MR in DKO keratinocytes resulted in physical and cooperative functional interactions that restored
the transcriptional response to GCs. In conclusion, our data have revealed that epidermal GR and MR act cooperatively to
regulate epidermal development and counteract skin inﬂammation.
Introduction
Glucocorticoid (GC) derivatives are the most effective
and widely prescribed compounds for treating
inﬂammatory and autoimmune diseases. However, their
therapeutic use is limited by the adverse side-effect proﬁle
that in skin includes epidermal thinning, dermal atrophy,
impaired wound healing and increased fragility, dehy-
dration and infection risk1–3. These adverse effects are
similar to symptoms of individuals with abnormally high
endogenous production of GCs (Cushing’s syndrome) as
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well as in the elderly population. GC deﬁciency (Addison’s
disease, also featuring mineralocorticoid deﬁciency) also
results in skin alterations4,5, highlighting the requirement
for appropriate GC levels for normal tissue function.
The skin prevents dehydration, mechanical trauma, and
infection6. The epidermis, the epithelial compartment of
the skin, is mainly composed of keratinocytes which
undergo terminal differentiation to generate the dead,
ﬂattened squames of the stratum corneum (SC), required
for barrier function6,7. Defects in differentiation are
associated with inﬂammation as a faulty epidermal barrier
allows the entrance of allergens that stimulate the
immune response leading to the prevalent inﬂammatory
skin disorders atopic dermatitis and psoriasis8,9.
GC synthesis in the adrenal cortex is controlled by the
hypothalamic–pituitary–adrenal (HPA) axis10. GCs exert
their effects through binding to the GC receptor (GR) and
the mineralocorticoid receptor (MR), structurally and
functionally homologous ligand-activated transcription
factors1,11–13. In response to endogenous hormones and
synthetic ligands, GR and MR dissociate from multimeric
cytoplasmic inhibitory complexes, undergo post-
translational modiﬁcations, translocate to the nucleus
and bind to GC response elements (GREs) in target genes.
The therapeutic actions of GC-activated GR occur
through distinct mechanisms, including: (i) physical
interaction (tethering) with pro-inﬂammatory transcrip-
tion factors such as NF-κB and AP-1, independent of
DNA-binding; (ii) antagonism with MAPKs p38, ERK,
and JNK, which act upstream of AP-1 and in the case of
p38, NF-κB; and (iii) transcriptional induction of anti-
inﬂammatory genes (e.g., Dusp1/Mkp1 and Tsc22d3/Gilz)
by binding to GREs1,11,14.
GR is ubiquitously expressed, however, MR shows a
more restricted expression pattern with highest levels in
kidney and cardiovascular tissues11–13. Both receptors are
expressed in the epidermis and its appendages5,15–18.
Importantly, MR has a 10-fold higher afﬁnity for GCs
than GR. Expression of the GC-inactivating enzyme 11-
beta hydroxysteroid dehydrogenase (HSD11B) type 2 in
tissues such as kidney and heart protects MR from con-
stant GC occupation and allows activation by aldosterone,
which has key roles in electrolyte balance10,13. In these
tissues, MR activation is involved in pathophysiological
effects ultimately leading to inﬂammation and ﬁbrosis and
MR antagonists are beneﬁcial for patients with cardio-
vascular and renal disease19. However, it is currently
accepted that MR exerts a broader range of functions in
non-classical tissues, such as in the brain, and that its
activation can be beneﬁcial19.
Our previous studies addressed the consequences of
epidermal loss of either GR (GR epidermal KO or
GREKO)15 or MR (MR epidermal KO or MREKO)16 in skin.
Newborn GREKO mice showed an impaired epidermal
barrier with increased proliferation and defective differ-
entiation while MREKO mice showed minor defects.
Numerous genes were upregulated in GREKO epidermis
which are overexpressed in psoriatic patients, however,
these alterations resolved spontaneously early after birth15
suggesting MR may have a compensatory role.
Adult GREKO and MREKO mice featured minor skin
defects but had worsened responses to inﬂammatory
triggers compared to controls (CO) demonstrating that
both epidermal GR and MR act as anti-inﬂammatory
mediators15,16. However, whether GR and MR cooperate
to counteract skin inﬂammation was unknown.
In this study, the generation and characterization of
mice and cell lines lacking epidermal expression of both
GR and MR (GREKO/MREKO double knockout, DKO) has
revealed cooperation between these receptors during
development as well as additive anti-inﬂammatory roles in
diseased skin.
Results
Combined loss of GR and MR severely impairs epidermal
development
To understand the relative roles of GR and MR in skin
homeostasis, we generated DKO mice with epidermal-
speciﬁc loss of both receptors, and analyzed the pheno-
typical and functional differences relative to single KO or
CO mice (Fig. 1).
DKOs were viable and fertile. At postnatal day 0 (P0),
DKOs displayed a striking phenotype of defective epi-
dermal differentiation, more severe than in GR or MR
single KOs, with patches of decreased granular layer and
minimal SC (Fig. 1a, arrows). Morphological changes were
evident, with keratinocytes appearing disorganized and
failing to ﬂatten suprabasally. The differentiation marker
loricrin showed reduced patchy expression in both GREKO
and DKO compared to MREKO and CO (Fig. 1a). Both
DKO and GREKO showed aberrant epidermal expression
of Keratin (K)6, though in the basal layer in GREKO and
the granular layer of DKO (Fig. 1a).
The epidermal alterations in P0 DKOs were likely due to a
delay in differentiation since SC was apparent at P1 (Fig. 1b).
Remarkably, we detected epidermal microabscesses in
DKOs, a phenotype not observed in single KO or CO mice
(Fig. 1b, c; asterisks). Microabscesses are associated with
inﬂammatory pathologies such as psoriasis and usually
contain neutrophil inﬁltrates20. Indeed, we detected Ly6G-
positive cells in DKO microabscesses (Fig. 1c). By P3, the
epidermis of DKO animals appeared almost entirely normal,
and microabscesses were being lost through desquamation
(Fig. 1b). We also detected increased levels of the phos-
phorylated (p-) forms of p38 and ERK in the epidermis of P0
DKO and single KOs relative to CO (Fig. 1c).
We assessed the expression of genes involved in epi-
dermal development (Krt77, Sprr2d) and inﬂammation
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(Mmp3, Slpi, Tslp, Lcn2, and S100a8) and found increased
mRNA levels in DKO vs. CO newborn epidermis (Fig. 1d).
Similar dysregulation of Krt77, Sprr2d, Mmp3, Slpi, and
Tslp was observed in GREKO but not MREKO epidermis,
suggesting GR-dependent regulation (Fig. 1d). On the
other hand, Hsd11b2 was drastically reduced in both DKO
and MREKO—but not GREKO—suggesting dependence on
MR (Fig. 1d). Sprr2d was increased in all KOs suggesting
involvement of both receptors in its regulation while
Hsd11b1 expression was not affected by the loss of either
or both receptors (Fig. 1d). Importantly, Lcn2 and S100a8
were upregulated in all KOs with additive increases in
DKO relative to single KOs, suggesting cooperative
actions (Fig. 1d).
The skin phenotype of DKOs resolved around P5 and
adult skin sections showed no major differences relative
to CO except for an increase in epidermal thickness
(Fig. S1a). These alterations were similar to those
observed in each single KO16,17 suggesting similar roles
for GR and MR in adult skin homeostasis.
However, the transcriptional response of DKO skin to
topically applied dexamethasone (Dex) was absent as
there was no induction of GC-target genes Zfp36, Ddit4,
and Fkbp51 or repression of Ccnd1 (Fig. S1b). These data
indicate that the absence of GR and MR in epidermis,
even though other skin cells have intact expression of
both receptors, is sufﬁcient to impair the GC-dependent
transcriptional activity in skin.
Fig. 1 Severe impaired epidermal differentiation and inﬂammation, increased phosphorylated-MAPKs, and gene dysregulation upon
combined loss of GR and MR. a Hematoxylin & eosin (H&E)-stainings (top) and loricrin and keratin(K)6 immunohistochemistry (middle, bottom) of
skin sections from postnatal day (P) 0. Control (CO), GR epidermal knockout (GREKO), MR epidermal knockout (MREKO) or combined GR and MR
epidermal knockout (DKO). Dotted line separates epidermis and dermis. Arrows: defective differentiation and minimal stratum corneum; hash: altered
stratum corneum. b H&E-stained sections of CO and DKO mouse skin at the indicated postnatal days (P1, P3). Asterisks: microabscesses. c
Immunostaining for Ly6G, phospho(p)-p38, and p-ERK of mouse skin from CO, DKO, GREKO, and MREKO P1 littermates. Asterisks: neutrophil-containing
microabscesses. d Gene expression was quantitated by RT-QPCR using epidermal RNA from P0 DKO, GREKO, and MREKO mice (relative to CO). Asterisks
indicate signiﬁcant differences relative to CO and hashes signiﬁcant differences between DKO and single KO: *, # < 0.05, ** < 0.01,
***, ### < 0.001; n > 3 in each experimental group
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Adult DKO mice show increased PMA-induced skin
inﬂammation
Next, we assessed the consequences of combined epi-
dermal loss of GR and MR in inﬂammation in vivo by
inducing ear edema via topical application of the phorbol
ester 12-myristate 13-acetate (PMA). PMA treatment
signiﬁcantly increased edema and epidermal thickness in
DKOs—but not in single KOs—relative to CO (Fig. 2a,
and S2). Importantly, only DKO ears displayed epithelial
microabscesses containing neutrophils after PMA treat-
ment (Fig. 2b, Ly6G, asterisks). We also detected
increased interfollicular expression of K6 in PMA-treated
DKO and single KOs vs. CO skin. However, while K6 was
detected throughout all epidermal layers in the DKO it
was restricted to suprabasal keratinocytes in the single
KOs (Fig. 2b). In PMA-treated DKO and single KO skin,
the nuclear p65-NF-κB was strongly increased in basal
and suprabasal keratinocytes relative to CO (Fig. 2b,
arrows).
Consistent with these results, PMA triggered increased
upregulation of the inﬂammatory markers Il6, S100a8,
and Mmp3 in DKO and single KOs relative to CO ear
epidermis (Fig. 2c). While Tslp was induced only in
GREKO and DKO, Il6 showed the strongest upregulation
in MREKO epidermis. There was an increased trend of
S100a8 expression in DKO as compared to GREKO or
MREKO although it did not reach statistical signiﬁcance;
however Mmp3 expression showed additive increases in
DKO relative to single KOs (Fig. 2c).
We asked whether the individual or combined absence
of epidermal GR and MR reduced the therapeutic effects
of GCs on skin inﬂammation by treating dorsal skin with
Fig. 2 Increased PMA-induced skin inﬂammation in DKO mice. a Representative images of H&E-stained sections of CO, DKO, GREKO, and MREKO
mouse ears after topical treatment with the phorbol ester 12-myristate 13-acetate (PMA) or vehicle (V). Large brackets: ear edema; small brackets:
epidermal thickness; asterisks: neutrophil-containing microabscesses. b Immunostaining for Ly6G, K6, and p65-NF-κB in skin samples from (a). c The
relative mRNA levels of Tslp, Il6, S100a8, and Mmp3 in PMA-treated CO, DKO, GREKO, and MREKO epidermis were quantitated by RT-QPCR. Asterisks
indicate statistically signiﬁcant differences relative to CO and hashes signiﬁcant differences of DKO relative to single KO: * < 0.05, **, ## < 0.01,
***, ### < 0.001; n > 4 mice per genotype
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PMA alone or in combination with Dex. In CO mice, Dex
reduced the PMA-induced epidermal thickening, K6
expression, and the number of BrdU-positive proliferating
keratinocytes (Fig. S3a–c). In contrast, these effects of Dex
were drastically reduced in DKOs and single KOs
(Fig. S3a–c). Also, the increased nuclear p65-NF-κB in
DKO and single KO epidermis remained elevated even
after PMA plus Dex treatment (Fig. S3b). These results
show that both epidermal GR and MR are required for the
anti-proliferative and protective actions of GCs in
inﬂamed skin.
Increased sensitivity of DKO to IMQ-induced psoriasis
correlates with decreased expression of GC targets
We next investigated the consequences of epidermal-
speciﬁc GR and MR loss in psoriasis using the imiquimod
(IMQ)-induced protocol which consists in topical repe-
titive applications of Aldara®, a cream containing 5% of
the toll-like receptor 7 (TLR7)-agonist IMQ, which
induces histopathological and molecular changes that
closely recapitulate the human disease21.
Mice were treated with IMQ and erythema and scaling
were scored daily, with increases in desquamation in DKO
relative to CO or single KOs observed from day 3 onwards
(Fig. 3a and S4). DKOs showed an increased response to
IMQ relative to CO, GREKO or MREKO mice, including
increased epidermal thickening and abnormal keratino-
cyte differentiation (retention of the nuclei in the SC or
parakeratosis; Fig. 3b, brackets, and arrowheads, respec-
tively). Focal loss of HSD11B2, normally expressed in
differentiated epidermis was observed in DKO and GREKO
(Fig. S5). Immunostaining of IMQ-treated skin sections
showed increases in p-p38 and p-ERK in the epidermis of
all KOs relative to CO animals (Fig. S5). Importantly,
DKOs showed features of increased disease severity not
apparent in single KOs, including abundant immune
inﬁltrates containing neutrophils resembling Munro-like
abscesses in psoriatic lesions (Fig. 3b, Ly6G).
Although the absence of GR and MR in keratinocytes
did not cause spontaneous psoriasis per se, we detected
constitutive upregulation of several genes contributing to
the disease such as Il17f, Il22, and Il23 in vehicle-treated
DKO skin relative to single KO or CO (Fig. 3c, and data
not shown). After IMQ treatment Il17f levels increased in
CO and single KO and remained high in DKOs. However,
the expression of the psoriasis marker Lcn2 did not differ
between genotypes in basal or disease conditions while
S100a8 was 2-fold upregulated in vehicle-treated DKO vs.
CO and MREKO (Fig. 3c).
Recent ﬁndings reported decreases in mRNA levels of
GR/NR3C1 and MR/NR3C2, as well as GC-target genes
FKBP51 and ZBTB16 in human psoriatic lesions22,23.
Consistently, we detected strong downregulation of Nr3c1
and Nr3c2 as well as Fkbp51 and Zbtb16 in IMQ-treated
CO skin (Fig. 3d, e). Importantly, Fkbp51 and Zbtb16
were constitutively downregulated in DKO relative to
CO mice (>20-fold) and IMQ treatment did not further
decrease their expression (Fig. 3e). In GREKO and
MREKO, Fkbp51 and Zbtb16 also showed decreased basal
expression relative to CO (2.5- to 3-fold) and IMQ
reduced their expression to a similar extent as in CO
(Fig. 3e).
Immortalized DKO keratinocytes show a unique
phenotype relative to GREKO, MREKO, and CO
To unequivocally decipher the cell-type speciﬁc roles of
GR and MR, we established immortalized DKO kerati-
nocyte cell lines from adult epidermis (Fig. S6), and per-
formed comparative assessment of their morphology,
degree of differentiation, and growth kinetics relative to
previously established single KO and CO cells16,24.
DKO keratinocytes showed reduced cell size relative to
CO or single KO, which was conﬁrmed by ﬂow cytometry
(Fig. 4a, b). The expression of the epithelial-speciﬁc
marker E-cadherin was absent only in GREKO keratino-
cytes consistent with its previously reported
epithelial–mesenchymal transition phenotype24. The
downregulation of E-cadherin in GR-deﬁcient but not
DKO cells suggests that keratinocyte alterations are not
due to intrinsic GR deﬁciency but rather to a pathological
role of MR in the absence of GR (Fig. 4c).
The expression of K5 was upregulated while the epi-
thelial marker p63 was downregulated in DKO relative to
the other cell lines (Fig. 4c). Overall, these data suggest
that both GR and MR are required in keratinocytes for the
proper expression of epithelial markers7,8, although their
individual or combined loss does not impede the
expression of the keratinocyte marker K5.
Examination of the growth rate of CO, single KO and
DKO keratinocytes in culture revealed higher prolifera-
tion of DKO and MREKO cells relative to GREKO and CO
with statistical signiﬁcance at day 7 (Fig. 4d). These data
are consistent with the known anti-proliferative role of
GR and MR in epidermis15,16,24.
Lack of GR and MR results in dysregulation of the MAPK/
MAPK phosphatase and NF-κB pathways in keratinocytes
It is well known that MAPKs positively regulate kera-
tinocyte proliferation and also that GC-activated GR
inhibits MAPK signaling14,25. GCs also control the gene
expression of negative MAPK regulators including the
Dusp1/Mkp1 and Dusp4/Mkp226.
We checked the total and phosphorylated protein levels
of MAPKs in CO, DKO, GREKO, and MREKO cells
(Fig. 5a). In single KO cells there were statistically sig-
niﬁcant increases of the p-p38/p38 and p-ERK/ERK ratios
relative to CO indicating that both receptors are required
to control these MAPKs. Also, as DKO cells showed
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quantitatively similar changes compared to single KO, our
data suggest that GR and MR target these MAPKs
through common pathways. In contrast, JNK activity was
unchanged among cell lines (Fig. 5a, b).
We found that the absence of MR in MREKO or DKO
cells, but not GR, correlated with statistically signiﬁcant
upregulation of MKP-1 (Fig. 5a, b). Conversely, in the
absence of GR, MKP-2 was upregulated to a similar extent
in GREKO and DKO keratinocytes while it was unchanged
in MREKO cells. While MKP-1 targets preferentially p38
and JNK, MKP-2 preferably dephosphorylates ERK and
JNK15. Previous studies in keratinocytes showed that GCs
transcriptionally induced Mkp1 while they downregulated
Mkp227. However, it has not been addressed whether this
regulation is mediated by MR or GR.
Therefore, we investigated whether the changes in
protein levels of these phosphatases were due to the lack
of transcriptional control by GR and/or MR. Dex strongly
induced Mkp-1 in CO and MREKO cultured keratinocytes
but not in GREKO or DKO, suggesting that GR is neces-
sary and sufﬁcient for the full induction of this gene
(Fig. S7). On the other hand, Dex repressedMkp-2 only in
CO cells, indicating that both GR and MR are required for
its regulation (Fig. S7). These ﬁndings indicate that GR
and MR have speciﬁc roles in modulating the expression
of MKP-1/2 in epidermal keratinocytes. In addition,
MKP-1/2 upregulation in DKO keratinocytes was not a
direct consequence of p38 or ERK over activation since
treatment with speciﬁc pharmacological antagonists did
not modify phosphatase levels (Fig. S8).
Fig. 3 Increased sensitivity of DKO to IMQ-induced psoriasis correlates with decreased expression of GC targets. a Score of scaling and
erythema in CO, DKO, GREKO, and MREKO mice treated with imiquimod (IMQ) for 6 days. *, differences of DKO relative to CO; #, differences of DKO
relative to GREKO; +, differences of DKO relative to MREKO; ·, differences of GREKO relative to CO; *, #, +, ·p < 0.05; **, ##, ++p < 0.01; +++p < 0.001; n > 5
mice per experimental group. b Representative images of skin sections of vehicle (V) and IMQ-treated mice that were H&E-stained or immunostained
for Ly6G. Brackets: epidermal thickening; arrowheads, abnormal keratinocyte differentiation; and asterisks, immune inﬁltrates containing neutrophils.
c–e Relative mRNA levels for indicated genes were quantitated by RT-QPCR in V and IMQ-treated skin of the indicate genotypes. *, comparison
between treatments within one genotype; #, comparison between genotypes within the same treatment; *, #p < 0.05, **, ##p < 0.01, ***, ###p < 0.001;
n > 4 in each experimental group
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We next assessed downstream AP-1 activity using
luciferase reporter assays and found constitutive increa-
ses in single KO (6-fold) and DKO cells (9-fold) relative
to CO (Fig. 5c), demonstrating that both receptors
are required for regulation of this inﬂammatory
signaling pathway. The increase in activity (1.5-fold)
observed between DKO and single KO cells indicates
cooperation between GR and MR. The pharmacological
inhibition of ERK but not p38 partially ameliorated the
AP-1 activity in DKO cells (Fig. 5c). The increased AP-1
activity in DKO cells even in the absence of active ERK
may reﬂect transcriptional repression mediated by
tethering of GR/MR to AP-1 or the lack of induction of
other negative repressors of this pathway. Moreover,
these mechanisms could account for the differences in
AP-1 activity observed between single KO and DKO
cells, despite having similar levels of ERK and p38
activation28.
Our recent work demonstrated that similar to GR, MR
has anti-inﬂammatory roles in inﬂamed skin at least
partially through inhibition of the NF-κB activity in ker-
atinocytes16. Consistent with this, in single KO cells, NF-
κB-luciferase activity was constitutively augmented by 3-
to 4-fold relative to CO and, remarkably, DKO cells
showed a 10-fold increase, indicating synergistic regula-
tion by GR and MR (Fig. 5d). Inhibition of p38 but not
ERK resulted in signiﬁcant decrease in NF-κB activity
(Fig. 5d). Cell fractionation and immunoﬂuorescence
analyses demonstrated a signiﬁcant increase in nuclear
p65 and a decrease in IκBα in DKO vs. CO keratinocytes,
another cause for the elevated NF-κB activity in these cells
(Fig. 5e-g).
Fig. 4 Immortalized DKO keratinocytes show a unique phenotype relative to GREKO, MREKO, and CO cells, with reduced cell size and altered
proliferation. a Representative phase contrast images of CO, DKO, GREKO, and MREKO keratinocytes. b Representative experiment for forward and
side scatter evaluated by ﬂow cytometry in CO, DKO, GREKO, and MREKO cells; n= 3. c Immunoblotting of cell lysates using E-cadherin, K5, p63, and
tubulin antibodies. d. Growth kinetics of cultured CO, DKO, GREKO, and MREKO keratinocytes. Asterisks indicated statistically signiﬁcant differences
relative to CO: *p < 0.05; n > 4 biological replicates per genotype
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Reinsertion of GR and MR in immortalized DKO
keratinocytes results in physical and functional
interactions that restore the transcriptional response to
GCs
To unequivocally demonstrate that the impaired acti-
vation of the MAPK pathway is due to the loss of GC
receptors, we attempted to reverse the relative increases
in p38 and ERK activities by reinsertion of empty vector
(EV), GR, MR, or both, into DKO cells (Fig. 6a). The
expression of either receptor resulted in signiﬁcant
decreases in p38 and ERK activities which reached similar
levels to those in CO keratinocytes (Fig. 6a, b). However,
the co-transfection of both receptors did not achieve
further decrease, which is consistent with the fact that the
loss of either or both receptors has the same consequence
for MAPK activity (Fig. 5a).
We next assessed GC-induced nuclear translocation of
GR and MR by co-transfection of both receptors into
DKO cells followed by Dex treatment. Immuno-
ﬂuorescence demonstrated nuclear co-localization of GR
and MR (Fig. 6c, IF). Also, Proximity ligation assays (PLA)
revealed physical interaction of GR and MR in the cyto-
plasm even in the absence of hormone and, upon Dex
treatment this interaction was detected speciﬁcally in the
nuclear compartment (Fig. 6c).
The formation of GR- and MR- homo- and hetero-
dimers has been previously reported29,30. To decipher the
relative contribution of GR and MR dimers in the
Fig. 5 Constitutively dysregulated MAPK/MKP pathways and over activation of the AP-1 and NF-κB pathways in epidermal keratinocytes
upon GR/MR loss. a Immunoblotting for p-p38, p38, p-ERK, ERK, p-JNK, JNK, MKP1/MKP2, and tubulin in cell extracts from CO, DKO, GREKO, and
MREKO cultured keratinocytes. b Quantitation illustrates p-p38/p38, p-ERK/ERK, p-JNK/JNK, MKP1/tubulin, and MKP2/tubulin ratios in all cell lines
relative to CO. Asterisks indicate statistically signiﬁcant differences relative to CO *p < 0.05, **p < 0.01, ***p < 0.001; n > 4 biological replicates per
genotype. c, d CO, DKO, GREKO, and MREKO cells were transfected with AP-1-luciferase (c) or NF-κB-luciferase (d) plasmids to assess reporter activities.
DKO cells were also treated with vehicle (V), the p38 inhibitor BIRB196 (BIRB), or the ERK inhibitor U0126 as indicated. Differences relative to CO (or V)
are indicated by asterisks and those between single KOs and DKO by hash signs: #p < 0.05; ***,###p < 0.001; n > 4 biological replicates per genotype. e
Immunoﬂuorescence for p65 (green) in CO and DKO cells counterstained with DAPI (blue). f Immunoblotting for p65, IκBα, tubulin and laminin A
(LAMA) of cytoplasmic (C) and nuclear (N) protein. g Quantitation relative to corresponding cell fractionation controls. Asterisks denote statistically
signiﬁcant differences relative to CO: *p < 0.05; **p < 0.01; n= 3 biological replicates per group
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transcriptional response to GCs in keratinocytes, we used
DKO cells that were transfected with distinct amounts
and ratios of each receptor along with a GRE-luciferase
reporter plasmid. In CO, Dex induced transactivation of
the GRE-luciferase reporter by ~7-fold while this response
was abolished in DKO keratinocytes (Fig. 6d). The
transfection of increasing amounts of GR into DKO cells
restored the response to Dex in a dose-dependent manner
while much higher doses of MR were required for
transactivation of the GRE-luciferase reporter (Fig. 6d).
However, while suboptimal doses of individually trans-
fected GR or MR did not result in reporter transactivation
after Dex treatment, their combined use achieved additive
effects restoring the response to a similar extent as in CO
cells (Fig. 6d). We also assessed MR recruitment to GRE-
containing regulatory sequences in the classical GC-target
Fig. 6 Reinsertion of GR and MR in DKO keratinocytes partially reverses elevated MAPK activity and restores the transcriptional response
to GCs. a Immunoblotting with lysates of DKO cells transfected with empty vector (EV), GR, MR, or both receptors, demonstrating expression of GR
and MR. Actin was used as a loading control. Immunoblotting for p-p38, p38, p-ERK, ERK, and tubulin in cell extracts from transfected DKO cells. CO
cells were used as an internal reference. b Quantitation illustrates p-p38/p38, and p-ERK/ERK ratios in transfected DKO cells and CO cells. Statistically
signiﬁcant differences relative to EV-transfected DKO cells are indicated by asterisks: *p < 0.05; **p < 0.01; n > 3 biological replicates per group. c
Immunoﬂuorescence for HA or GFP in DKO keratinocytes transfected with HA-GR or GFP-MR and treated with vehicle (V) or Dex. Proximity ligation
assays (PLA) in DKO cells co-transfected with both HA-GR and GFP-MR revealed physical interaction of the receptors in the absence and presence of
hormone. d Luciferase assay of DKO cells transfected with indicated relative amounts of GR and MR expression vectors along with GRE-luciferase
plasmid then treated with vehicle or Dex. CO cells were used as a reference. Hashes denote statistically signiﬁcant differences in GR and/or MR
transfected relative to EV DKO transfected cells; asterisk shows signiﬁcant transactivation upon Dex treatment in CO cells: #p < 0.05; ##,**p < 0.005;
###p < 0.001; n > 5 biological replicates per group. e Chromatin immunoprecipitation-QPCR to assess MR recruitment to GRE-containing Gilz
regulatory sequences assays in DKO keratinocytes expressing MR or MR+ GR after treatment with vehicle (V) or Dex (100 nM) for 2 h. *p < 0.05; n= 3
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Gilz by chromatin immunoprecipitation-qPCR assays and
found that binding was only detected when GR was also
present (Fig. 6e).
These data taken together with those showing physical
interaction between receptors support the functional and
cooperative role of GR and MR in mediating GC tran-
scriptional responses in keratinocytes.
Discussion
While the crucial role of GR in regulating epidermal
morphogenesis, skin wound repair, cutaneous inﬂamma-
tion, and tumorigenesis has been reported5, the knowl-
edge regarding MR function in skin biology is much more
limited. Studies have focused on MR as responsible for
some of the cutaneous undesired side-effects when GCs
are in excess16–18. Likewise, it was reported that under
physiological conditions, GR but not MR is essential for
normal cardiac function and that the adverse effects in the
cardiomyocyte-GR KO mice were due to GC-induced MR
over activation (rather than to the loss of GR)31,32.
By using genetic and pharmacological approaches in
mice and human skin explants, we and others demon-
strated that blockade of the MR effectively improved GC-
induced skin atrophy5,16,18. However, caution is advised
for treating inﬂamed skin with GCs and MR inhibitors as
their combined use decreased the anti-inﬂammatory
actions of GCs in SDS-treated human skin explants33.
Given that GR−/− and MR−/− mice die perinatally34,35
assessing the combined actions of both receptors in vivo
has been precluded. The generation of epidermal DKO
mice has allowed us to unequivocally demonstrate the
individual and combined roles of GR and MR in skin
pathophysiology.
The combined deletion of epidermal GR and MR
resulted in a severe skin phenotype at birth relative to
single KOs suggesting cooperative and unique roles of GR
and MR in modulating epidermal development and
inﬂammation (Fig. 1). We also demonstrate that in
response to PMA and IMQ, epidermal GR and MR have
anti-inﬂammatory roles in adult skin by targeting the
MAPK/AP-1 and NF-κB pathways and repressing the
expression of inﬂammatory mediators. Also, the fact that
neutrophil-containing microabscesses were only detected
in DKO mice, during development or after inﬂammatory
triggers, support cooperation between these receptors.
DKO were more susceptible to PMA and IMQ-induced
psoriasis than CO while GREKO and MREKO mice showed
an intermediate response. While the combined inactiva-
tion of epidermal GR and MR is not sufﬁcient to cause
spontaneous psoriasis it contributes to sustained inﬂam-
mation (e.g., increased Il17f levels) and ultimately
increases the susceptibility of DKOs to this disease
(Fig. 3). In DKO skin, impaired GC signaling contributes
to the lack of negative regulation of pro-inﬂammatory
genes and a defective induction of anti-inﬂammatory
mediators. These data are consistent with recent reports
demonstrating that defective local GC production in skin
—as this organ can synthesize and metabolize GCs—36,37,
could contribute to the pathogenesis of psoriasis38.
Our data suggest that the role of distinct GR- and MR-
homo- and hetero-dimers29,30 is relevant for regulating
gene expression (Fig. 6). This raises the question of the
underlying mechanisms for speciﬁcity given that both
receptors can theoretically bind to identical GREs. One
possible explanation is that differential interactions of GR
or MR with other transcriptional regulators result in non-
overlapping transcriptional activities. In cultured kerati-
nocytes, either GR or MR were transcriptionally efﬁcient
in response to GCs, although GR showed much higher
transactivation capability relative to MR. However, while
suboptimal doses of GR and MR were individually unable
to transactivate a GRE-containing reporter, co-
transfection of both receptors resulted in functional
interaction and additive transcriptional actions (Fig. 6).
In conclusion, we provide insights into the relative roles
of GR and MR in keratinocytes by generating mice and
cell lines lacking both receptors, which may be useful for
better understanding the consequences of impaired GC
signaling in the skin, and ultimately improving GC-based
skin therapies.
Materials and methods
Antibodies and reagents
Unless otherwise speciﬁed all chemicals were from
Sigma. Antibodies were from Biolegend: HA (MMS-
101P), K5 (PRB-160P), K6 (PRB-169P), Loricrin (PRB-
145P); Santa Cruz Biotechnology: p38α (sc-535), p63 (sc-
8431), p65-NF-κB (sc-372), ERK (sc-154), GR (sc-1004),
HSD11B2 (sc-20176), IκB(sc-371), Mkp1/2 (sc-1102), MR
(sc-11412, ChIP), LaminA (sc-6214); Abcam: MR
(ab64457); Cell Signalling Technology: p-ERK (Thr202/
Tyr204; #4376), p-p38 (#9211S and #4631 for immuno-
histochemistry), p-JNK (#9251), JNK (#9252); Thermo-
Fisher: GFP (A6455); Sigma: Tubulin (T6199), Actin
(A2066); Roche: BrdU (11170376001) and BD Bios-
ciences: E-cadherin (610181), Ly6G (551459). Secondary
biotin-conjugated anti-rabbit, anti-mouse and anti-rat
antibodies (Jackson ImmunoResearch) and secondary
Alexa Fluor® anti-rabbit (555, A-31572) antibody (Ther-
moFisher) were used for immunostaining. Secondary
peroxidase-conjugated anti-rabbit (NA934), anti-mouse
(NA931) antibodies (GE Healthcare), and anti-goat
(Jackson Immunoresearch) were used for
immunoblotting.
Animal experimentation
Animal experimentation was conducted according to
current Spanish and European regulations and approved
Bigas et al. Cell Death and Disease  (2018) 9:588 Page 10 of 14
Ofﬁcial journal of the Cell Death Differentiation Association
by our institution’s ethics committee (approval ID for
project SAF2014-59474-R). Mice were maintained at 12
light/12 dark cycle, caged in groups (3–6 per cage), and
had access to ad libitum food and water. Unless otherwise
indicated, 8-week old mice in the telogen phase of the hair
cycle were used for experiments and were treated and
killed in the morning.
MRloxP/loxP//GRloxP/loxP mice were generated by inter-
crossing MRloxP/loxP with GRloxP/loxP animals39,40. To
generate double GR/MR epidermal knockout mice (DKO;
keratin 5 (K5)-Cre//MRloxP/loxP//GRloxP/loxP), K5-Cre//
MRloxP/loxP (MREKO)16 males were bred with MRloxP/loxP//
GRloxP/loxP females. K5-Cre//GRloxP/loxP (GREKO) mice
have been previously described15. The colony was main-
tained by crossing DKO males with MRloxP/loxP//GRloxP/
loxP females. MRloxP/loxP//GRloxP/loxP littermates were used
as experimental controls (CO).
Skin phenotype of developing and newborn CO and
DKO littermates was assessed macroscopically and his-
tologically at E18.5 (16 CO, 20 DKO), P0 (5 CO, 5 DKO),
P1 (12 CO, 11 DKO), and P3 (4 CO, 4 DKO). Epidermis
for preparation of RNA or protein from P0/P1 mice was
isolated by incubating dorsal skin with 1 mg/ml dispase II.
Samples were from 7 CO, 9 DKO, 2 GRloxP/loxP, 4 GREKO,
2 MRloxP/loxP, and 4 MREKO mice.
To determine keratinocyte proliferation, mice were
injected with BrdU (130 μg/g of body weight) 1 h before
killing. To assess GC-mediated gene expression, dorsal
skin (n ≥ 4 per experimental group) was treated with
Vehicle (Acetone) or Dex (8 μg/200 μl) 24 h prior to kill-
ing. The phorbol ester PMA was applied to both sides of
mouse ears (8 μg/50 μl) 48 h prior to killing (n ≥ 4 per
experimental group). To test the anti-inﬂammatory
capacity of GCs, vehicle or Dex were applied (16 μg/200
μl) to dorsal skin 24 h prior to and upon treatment with
PMA (8 μg/200 μl) 48 h prior to killing (n ≥ 4 per experi-
mental group).
For IMQ-induced psoriasis, mice between 8–12 weeks
old, (n ≥ 5 per experimental group) were used and Aldara®
(5% IMQ, 3M Pharmaceuticals; 62.5 mg) was applied to
dorsal skin daily for 6 consecutive days. On day 7, mice
were killed. Macroscopic parameters such as skin ery-
thema and scaling were scored daily independently on a
scale from 0 to 5: 0, none; 1, slight; 2, moderate; 3,
marked; 4, very marked; 5, severe.
Histochemical analysis
Tissues collected from mice were ﬁxed in 4% PFA or
70% ethanol and parafﬁn-embedded for histopathological
analysis as described15. 4 µm-thick sections were either
stained with hematoxylin–eosin or used for immuno-
ﬂuorescence (see below) or immunohistochemistry per-
formed following manufacturers’ indications for
antibodies. After incubation with primary and secondary
biotin-conjugated antibodies, immunoreactivity was
revealed using the VECTASTAIN® Elite ABC-Peroxidase
Staining Kit (Vector Labs) and the sections were coun-
terstained with hematoxylin, mounted and analyzed using
a Leica DM1000 microscope, Leica EC3 camera and LAS
EZ software (Leica Biosystems, Wetzlar, Germany).
Quantitation of BrdU-positive nuclei was performed by
counting 100 hematoxylin-stained nuclei in the basal layer
of the interfollicular epidermis in 6 random areas per
immunostained section. Data were expressed as percen-
tages relative to total hematoxylin-stained nuclei (n ≥ 4
biological replicates per experimental group). Measure-
ments of ear edema and epidermal thickness were done
using Image J software as described17.
Immunoblotting
All protein extraction buffers were supplemented with
Complete protease and phosphatase inhibitor cocktails
(Roche). Whole cell protein extracts from cultured kera-
tinocytes were prepared using RIPA buffer and those from
mouse tissues were prepared by pulverizing frozen tissue,
then subjecting it to 3 freeze thaw cycles in 20mM
HEPES pH7.9, 0.4M NaCl, 1 mM EDTA, 1 mM EDTA,
25% glycerol, then adding IGEPAL® CA-630 NP-40 to a
ﬁnal concentration of 1%. Nuclear cytoplasmic fractio-
nation was carried out as described41. Samples (25–30 μg/
lane) were boiled in Laemmli buffer, separated on SDS-
PAGE and transferred to nitrocellulose membranes (GE
Healthcare). Membranes were blocked and incubated with
speciﬁc primary antibodies then peroxidase-conjugated
secondary antibodies following manufacturers’ indications.
Immunoreactive signal was detected with Pierce ECL Plus
Western Blotting Substrate (ThermoFisher) and the Ima-
geQuant 4000 Biomolecular Imager (GE Healthcare, Little
Chalfont, UK). Band intensities were quantitated using
Image J software. All signals were normalized to loading
controls (tubulin, actin or laminA).
RNA isolation and quantitative RT-PCR
Trizol (ThermoFisher) was used to extract RNA from
cells, whole skin or epidermis. In the cases of whole skin
or epidermis, a polytron (PT1600E, Kinematica, Luzern,
Switzerland) was used to homogenize samples. cDNA was
generated using RevertAid H Minus Reverse Tran-
scriptase (ThermoFisher) and oligo dT primers (Ther-
moFisher). RT-qPCR was performed in the 7500 Fast Real
Time PCR System (Applied Biosystems, Carlsbad, CA)
using speciﬁc oligonucleotides (0.3 μM each) and Fas-
tStart Universal SYBR Green Master ROX (Roche). Hprt1
was used as housekeeping gene. Oligonucleotide
sequences can be found in Table S1. Technical triplicates
were used; and at least three biological replicates per
experiment group were assessed to calculate the mean
value ± SD.
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Cell culture and treatments
Mouse keratinocyte cell lines were established following
published protocols42,43. Brieﬂy, keratinocytes were iso-
lated from 8-wk-old female mouse dorsal skin and cul-
tured on mitomycin C treated J2-3T3 feeders in type I
collagen-coated ﬂasks in DMEM-Ham’s F12 (3:1) medium
(ThermoFisher) supplemented with 1.8 × 10−4mol/l
adenine, 0.35 mM calcium, 7.5% FBS Gold (Biowest), 100
U/ml penicillin/100 μg/ml streptomycin (Biowest), 2 mM
glutamine (Biowest), 0.25 μg/ml amphotericin B (Bio-
west), 5 μg/ml insulin, 10−10M cholera toxin, and 10 ng/
ml EGF (Peprotech). Following approximately 8 passages,
spontaneously immortalized lines arose, which were
maintained using the above conditions.
To evaluate response to GCs, cells were grown over-
night in medium containing charcoal-stripped serum to
deplete steroids, and then treated with vehicle (EtOH) or
100 nM Dex for indicated time periods. In speciﬁed
experiments, cells were treated with 100 nM PMA, 10 μM
BIRB196, or 5 μM U0126 (Merck Millipore).
Plasmids, transfections, and luciferase assays
Two mouse GRalpha constructs were generated, one
untagged (pcDNA3-GR) and the other with an N-
terminal HA tag (pcDNA3-HAGR). The cDNA encod-
ing GR from pSV2Wrec44 was ampliﬁed by PCR and then
subcloned into the BamH1-XhoI sites of pcDNA3 (Invi-
trogen). Constructs were sequence veriﬁed prior to use
(Table S1).
Keratinocytes at 70–90% conﬂuence were transfected
with combinations of the following plasmids: pcDNA4
(ThermoFisher), pcDNA4-MR45, pcDNA3-GR, pGRE2EIB-
Luciferase46, pGL3-NF-KB-5×-Luciferase47, −73/+63
Collagenase-Luciferase48, and the internal control pRL-
SV40 Renilla (Promega) using Lipofectamine 2000 Reagent
(ThermoFisher). Luciferase activity was measured using the
Dual-Luciferase® Reporter Assay System (Promega) and a
Wallac 1420 Victor2 Microplate Reader (Perkin Elmer,
Waltham, Massachusetts). Fireﬂy-luciferase levels were
normalized to those of Renilla luciferase.
Proliferation assays
Overall, 250 keratinocytes were plated per well (n= 4
per genotype and time point) in 96-well plates on day 0, 3,
5, and 7, 20 µl per well of CellTiter 96® AQueous One
Solution Cell Proliferation Assay Reagent (Promega) was
added and incubated for 3 h at 37 °C. Absorbance was
measured at 490 nm using a Wallac Victor2 1420 multi-
label counter (Perkin Elmer).
Flow cytometry
Following trypsinization, resuspension in serum-
containing media, and washing with PBS, cultured kera-
tinocytes were resuspended in DPBS+ 2% BSA. Forward
and side scatter were evaluated using a BD FACS
Canto Flow Cytometer (Franklin Lakes, New Jersey) and
data were analyzed using FlowJo Software (BD
Biosciences).
Immunoﬂuorescence and proximity ligation assay (PLA)
Keratinocytes were cultured on collagen I-coated cov-
erslips, ﬁxed with 4% PFA and permeabilized with 0.2%
Triton X100 in PBS prior to blocking with 5% donkey
serum in PBS and overnight incubation with primary
antibodies at 4 °C. The following day, samples were
washed with PBS, and incubated 1 h with secondary
antibodies and DAPI (ThermoFisher). The same protocol,
omitting the permeabilization step, was used for dewaxed
sections of parafﬁn-embedded EtOH-ﬁxed mouse skin.
Samples were mounted using Mowiol (Calbiochem) and
DABCO and then analyzed using a Leica DM RXA2
ﬂuorescent microscope.
Proximity ligation assays (PLA) were performed as
described with PLA Duolink® In Situ Red Starter Kit
Mouse/Rabbit (Sigma)49. Brieﬂy, for detection of GR/MR
interactions, GFP-MR44 and HA-GR constructs were
transfected into DKO cells at a 1:1 ratio, then cells were
treated with Dex 100 nM for 16 h. Protein interaction was
detected using anti-GFP and anti-HA primary antibodies
diluted in Antibody Diluent solution overnight at 4 °C. As
negative controls, cells transfected with either GFP-MR or
HA-GR were used.
Chromatin immunoprecpitation
MR chromatin immunoprecipitations were performed
as described using DKO keratinocytes transfected with 1:1
ratios of pcDNA3-empty vector and pcDNA4-MR or
pcDNA3-GR and pcDNA4-MR50. QPCR was performed
to determine the relative ampliﬁcation of sequences cor-
responding to a Gilz enhancer in Dex- vs. vehicle-treated
chromatin immunoprecipitations, which were normalized
to the ampliﬁcation values of respective inputs (primers;
Supplementary Table S1).
Statistical analysis
Experimental data were analyzed using IBM SPSS Sta-
tistics software. In all graphs, mean values ± SD are
shown. When statistical analysis was performed with
relative values, data were ﬁrst subjected to logarithmic
transformation. Prior to parametric testing, the Levene’s
test was used to determine whether samples within
groups had equal variance. For comparisons between two
experimental groups, we used the Student’s unpaired two-
tailed t-test. For comparisons among more than two
experimental groups, we used the one-way ANOVA,
which if statistically signiﬁcant was followed by a post hoc
Tukey multiple comparison test. P values <0.05 were
considered statistically signiﬁcant.
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